GDF-15 and the Effect of Empagliflozin in Heart Failure: Findings from the EMPEROR Program.

Joao Pedro FerreiraMilton PackerJaved ButlerGerasimos FilippatosStuart J PocockJames L JanuzziNaveed SattarSandra González MaldonadoMarina Panova-NoevaMikhail SuminSerge MassonStefan D AnkerFaiez Zannad

Published in: European journal of heart failure (2023)

GDF-15 is a marker of worse heart failure severity, is an independent predictor of major heart failure outcomes and may be associated with more pronounced benefits of empagliflozin. GDF-15 is increased among metformin users, and empagliflozin was associated with an increase in GDF-15 levels, primarily in patients not receiving metformin. This article is protected by copyright. All rights reserved.

Keyphrases

heart failure
end stage renal disease
left ventricular
ejection fraction
chronic kidney disease
atrial fibrillation
newly diagnosed
acute heart failure
cardiac resynchronization therapy
peritoneal dialysis
prognostic factors
patient reported outcomes
metabolic syndrome
adipose tissue
glycemic control